Voxvoganan for COVID-19: real-time analysis

Download Image

Post

c19early.org

Voxvoganan for COVID-19

1 study with 23 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 Voxvoganan studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−29%

Viral clearance (1)−29%

RCTs (1)−29%

Early (1)−29%

00.511.5+

← Voxvoganan
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Voxvoganan (LTX-109, Lytixar) is a synthetic cationic amphipathic antimicrobial peptidomimetic (small peptide-mimetic) designed to mimic host-defense peptides.


May 1 2022	Lütken et al., NCT04854928	A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.
May 1 2022	29% worse viral clearance (p=0.8). RCT 33 patients up to 6 days from symptom onset, showing no significant difference in short-term viral load change with LTX-109.